On February 20, 2013 the United States Food and Drug Administration announced an update to its prior warnings about using codeine in children who have undergone surgery for tonsillectomy and/or adenoidectomy. Specifically, the FDA issued a drug safety communication, advising patients that it would require pharmaceutical manufacturers of codeine-containing products to add a black-box warning […]
VICTOZA (liraglutide) – a glucagon-like peptide-1 (GLP-1) receptor agonist commonly used to treat type 2 adult diabetes mellitus. FDA approved uses: Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Available dosage forms: Solution for subcutaneous injection, prefilled multi-dose pen delivering doses of […]
BYETTA (exenatide) – a glucagon-like peptide-1 (GLP-1) receptor agonist commonly used to treat type 2 adult diabetes mellitus. FDA approved uses: Byetta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Available dosage forms: Solution for subcutaneous injection, prefilled multi-dose pen delivering doses of […]
On February 8, 2013 the U.S. Food and Drug Administration approved a new drug to treat multiple myeloma. The drug, Pomalyst (pomalidomide) is approved for use in patients whose disease has progressed after being treated with other cancer drugs. Multiple myeloma is a form of blood cancer that primarily affects older adults and arises from […]